Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Roche Holding, Philip Morris, HSBC, AMD, and Lockheed Martin

by Zacks Equity Research

Roche Holding, Philip Morris, HSBC, AMD, and Lockheed Martin are part of Zacks top Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Roche, Philip Morris & HSBC

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Philip Morris International Inc. (PM), and HSBC Holdings plc (HSBC).

Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug

by Zacks Equity Research

Repare Therapeutics (RPTX) signs a licensing agreement with Roche (RHHBY) to develop its lead candidate for solid tumor indications.

Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy designation to Sanofi's (SNY) efanesoctocog alfa for the treatment of people with hemophilia A.

Roche's (RHHBY) Evrysdi Gets FDA Nod for Label Extension

by Zacks Equity Research

The FDA approves a label expansion of Roche's (RHHBY) SMA drug Evrysdi to include less than two-month old babies with SMA.

The Zacks Analyst Blog Highlights AstraZeneca, Merck, Roche, J&J, and Pfizer

by Zacks Equity Research

AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids

by Kinjel Shah

European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.

Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL

by Zacks Equity Research

Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.

Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe

by Zacks Equity Research

Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The recent label expansion nod to Oxbryta is a positive. However, sole dependence on Oxbryta for growth is a concern.

Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?

by Zacks Equity Research

Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

Seagen (SGEN) Posts Positive Data from New Study on Tukysa

by Zacks Equity Research

Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.

ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review

by Zacks Equity Research

ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.

5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio

by Zacks Equity Research

We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.

Kinjel Shah headshot

Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update

by Kinjel Shah

Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.

    Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down

    by Zacks Equity Research

    Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.

    Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates

    by Zacks Equity Research

    Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.

    Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues

    by Zacks Equity Research

    Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.

    ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates

    by Zacks Equity Research

    ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.

    Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus

    by Zacks Equity Research

    Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.

    Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y

    by Zacks Equity Research

    Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.

      Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust

      by Zacks Equity Research

      Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.

      Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark

      by Zacks Equity Research

      Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.

      Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected

      by Zacks Equity Research

      Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.

      Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig

      by Zacks Equity Research

      Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.

      Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates

      by Zacks Equity Research

      Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.